CeriBell, Inc.
CBLLNASDAQHealthcareMedical - Devices
Previous close
$24.20
−$0.11 · -0.45%
CBLL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
73
Undervalued
Momentum
52
Neutral
Sentiment
53
Mixed
Risk resilience
55
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Xingjuan Chao
- Listed since
- Oct 11, 2024
- Employees
- 327
Market position
Day range
Current $24.20
52-week range
Current $24.20
- Open
- $24.025
- Previous close
- $24.31
- Volume
- 292.63K
- 0.8× average
- Average volume
- 363.86K
- Average daily volume
- Market cap
- 918.21M USD
- Beta
- 0.81
- Market reference 1
- 50-day average
- $19.5216
- +23.97% above average
- 200-day average
- $19.1607
- +26.30% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 783.17M USD
- P/E (TTM)
- -13.75×
- P/B (TTM)
- 7.17×
- P/S (TTM)
- 9.01×
- EV / EBITDA
- -15.61×
- Earnings yield
- -6.67%
- Free cash flow yield
- -5.19%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 88.90%
- Operating margin
- -68.62%
- Net margin
- -64.73%
- Return on equity
- -34.38%
- Return on assets
- -27.28%
- Return on invested capital
- -32.86%
Financial health
- Debt / equity
- 0.17×
- Current ratio
- 9.73×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 89.06M USD | 65.44M USD | 45.23M USD | 25.92M USD |
| Cost of goods sold | 10.79M USD | 8.69M USD | 7.06M USD | 4.43M USD |
| Gross profit | 78.27M USD | 56.75M USD | 38.16M USD | 21.49M USD |
| Research and development | 19.14M USD | 13.56M USD | 9M USD | 7.24M USD |
| Selling, general, and administrative | 117.53M USD | 82.9M USD | 59.21M USD | 50.27M USD |
| Operating expenses | 136.68M USD | 96.46M USD | 68.2M USD | 57.51M USD |
| Interest expense | 1.89M USD | 1.99M USD | 2.1M USD | 1.6M USD |
| Depreciation and amortization | 1.34M USD | 1.14M USD | 847K USD | 497K USD |
| Operating income | −58.4M USD | −39.71M USD | −30.04M USD | −36.02M USD |
| Net income | −53.41M USD | −40.46M USD | −29.46M USD | −37.16M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 50%
- 4 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -17.58%
- 8 comparable reports
- Latest EPS result
- -0.51
- Estimate -0.47 · Miss by 8.24%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
CBLL news
Continue in GoAI
Research CBLLresearch.disclaimer